The Vanguard Group 13D and 13G filings for Esperion Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 2:23 pm Unchanged |
2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR |
The Vanguard Group | 13,043,077 6.640% |
0 (Unchanged) |
Filing |
| 2024-11-04 1:33 pm Unchanged |
2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR |
The Vanguard Group | 13,043,077 6.640% |
0 (Unchanged) |
Filing |
| 2024-11-04 12:09 pm Purchase |
2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR |
The Vanguard Group | 13,043,077 6.640% |
7,905,327 (+153.87%) |
Filing |
| 2024-02-13 5:04 pm Purchase |
2023-12-29 | 13G | Esperion Therapeutics, Inc. ESPR |
The Vanguard Group | 5,137,750 4.520% |
877,286 (+20.59%) |
Filing |
| 2023-02-09 11:19 am Purchase |
2022-12-30 | 13G | Esperion Therapeutics, Inc. ESPR |
The Vanguard Group | 4,260,464 5.780% |
499,025 (+13.27%) |
Filing |
| 2022-02-10 08:11 am Purchase |
2021-12-31 | 13G | Esperion Therapeutics, Inc. ESPR |
The Vanguard Group | 3,761,439 6.060% |
1,396,132 (+59.03%) |
Filing |
| 2021-02-10 10:52 am Sale |
2020-12-31 | 13G | Esperion Therapeutics, Inc. ESPR |
The Vanguard Group | 2,365,307 8.480% |
-282,604 (-10.67%) |
Filing |